EUVIMEDEUVIMED entdecken
Crossref

CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin

Jackson K B Cahn iD, Henry Ludwicki, Jillian Shingler, Shannon Gulvin, Young Zhang, Adam Kristopeit, Christopher Ton, Michael A Winters, James M Wagner, Jeffrey Moore iD

Biotechnology and Bioengineering · 2025

DOI: 10.1002/bit.29028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2025. Verfasst von Jackson K B Cahn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Process Research & Development, Merck & Co. Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Gene Editing, Fibronectins, CRISPR-Cas Systems, Viral Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Removal of host cell components is a significant cost driver in the production of live virus vaccines. Filtration processes such as tangential flow filtration can be effective in this capacity by leveraging the relative size difference between viral particles and host proteins; however, filtration membranes can be fouled by larger proteins, particularly those of the extracellular matrix. In this study, we used CRISPR editing to insert the recognition element of the highly‐selective TEV protease into various positions of the gene encoding fibronectin in the genome of the Vero cell line, a common platform for viral production. By screening edited cell lines, we identified a promising candidate line in which fibronectin could be effectively removed by treating with the protease during processing, eliminating filter fouling and allowing for viral purification without the need for costly chromatography steps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingFibronectinsCRISPR-Cas SystemsViral VaccinesAnimalsChlorocebus aethiopsVero CellsProteolysisVaccines, Attenuated

Stichwörter der Autor:innen

CRISPR editingfibronectinlive‐virus vaccinesprotein removalultrafiltrationvirus purification

Substanzen

FibronectinsViral VaccinesVaccines, Attenuated

Autor:innen und Institutionen

  • Process Research & Development, Merck & Co. Inc., Rahway, New Jersey, USA.
  • Process Research & Development, Merck & Co. Inc., West Point, Pennsylvania, USA.
  • Analytical Research & Development, Merck & Co. Inc., West Point, Pennsylvania, USA.

ORCID-Profile: Jackson K B Cahn, Jeffrey Moore

Zitieren

APA

Cahn, J. K. B., Ludwicki, H., Shingler, J., Gulvin, S., Zhang, Y., Kristopeit, A., Ton, C., Winters, M. A., Wagner, J. M., & Moore, J. (2025). CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.29028

Vancouver

Cahn JKB, Ludwicki H, Shingler J, Gulvin S, Zhang Y, Kristopeit A, et al. CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin. Biotechnology and Bioengineering. 2025. doi:10.1002/bit.29028

BibTeX
@article{Cahn2025,
  author = {Cahn, Jackson K B and Ludwicki, Henry and Shingler, Jillian and Gulvin, Shannon and Zhang, Young and Kristopeit, Adam and Ton, Christopher and Winters, Michael A and Wagner, James M and Moore, Jeffrey},
  title = {CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin},
  journal = {Biotechnology and Bioengineering},
  year = {2025},
  doi = {10.1002/bit.29028}
}
Kostenlos starten →